Erratum for the Research Article: 'mTORC1 Inhibition Is Required for Sensitivity to PI3K p110α Inhibitors in PIK3CA -Mutant Breast Cancer' by M. Elkabets, S. Vora, D. Juric, N. Morse, M. Mino-Kenudson, T. Muranen, J. Tao, A. B. Campos, J. Rodon, Y. H. Ibrahim, V. Serra, V. Rodrik-Outmezguine, S. Hazra, S. Singh, P. Kim, C. Quadt, M. Liu, A. Huang, N. Rosen, J. A. Engelman, M. Scaltriti, J. Baselga

Autor:	P. Kim, Jeffrey A. Engelman, Maurizio Scaltriti, Vanessa Rodrik-Outmezguine, Saswati Hazra, Yasir H. Ibrahim, J. Baselga, Violeta Serra, Natasha Morse, Dejan Juric, Taru A. Muranen, Ana Bosch Campos, Jessica J. Tao, Manway Liu, Alan Huang, Mari Mino-Kenudson, Jordi Rodon Ahnert, Cornelia Quadt, Sadhna Vora, Moshe Elkabets, Sharat Singh, Neal Rosen
Rok vydání:	2018
Předmět:	Breast cancer business.industry Mutant Cancer research Translational medicine Medicine Research article General Medicine mTORC1 business medicine.disease PI3K/AKT/mTOR pathway
Zdroj:	Science Translational Medicine. 10
ISSN:	1946-6242 1946-6234
DOI:	10.1126/scitranslmed.aav9425
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::0707406bbadb2f75b8ac24ed714caf4e https://doi.org/10.1126/scitranslmed.aav9425 Zobrazit plný text záznamu